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ABSTRACT
In 1983, just two years after the introduction of the oxymino-b-lactams to the market , the first extended-
spectrum b-lactamases were isolated in Germany from Klebsiella pneumoniae strains. Since then several
outbreaks have been reported in many European countries and the USA, and nowadays in several
places worldwide the problem seems to reach endemic dimensions, with rates exceeding 50% in some
countries, such as Portugal and Turkey. On the other hand not only K. pneumoniae but also Escherichia coli
strains, with Enterobacter aerogenes predominating among the other enterobacteriaceal species, are
increasingly reported as ESBL producers. In this review types, molecular characteristics, detection
methods, epidemiology as well as interventions for therapy and antibiotic strategies to prevent and
control infections caused by ESBL-producing microorganisms, are presented and discussed.
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INTRODUCTION
It has been well known for many years that
several genera of Gram-negative bacteria possess
naturally occurring, chromosomally mediated
b-lactamases, which are thought to have evolved
from penicillin-binding proteins as a result of the
selective pressure exerted by soil organisms pro-
ducing b-lactams [1]. The first plasmid-mediated
b-lactamase isolated from Gram-negative bac-
teria, which hydrolysed penicillin and penicillin
derivatives, such as ampicillin, carbenicillin, pip-
eracillin and first-generation cephalosporins, was
TEM-1, described in the early 1960s [2]. This
enzyme was found in a blood culture isolate of
Escherichia coli from a Greek patient named
Temoniera, hence the designation TEM. As the
latter enzyme was plasmid and transposon medi-
ated, it spread easily to many different species of
Gram-negative bacteria [3]. Subsequently, SHV-1
b-lactamase, chromosomally encoded in the
majority of Klebsiella pneumoniae and plasmid
mediated in E. coli, was reported [4]. It was just
2 years after the introduction of oximino-b-lac-
tams, such as cefotaxime, ceftazidime and ceftri-
axone, and the oximino-monobactam, aztreonam,
which were specifically designed to resist the
hydrolytic action of b-lactamases, that extended-
spectrum b-lactamases (ESBLs) were first isolated
in Germany in 1983 from K. pneumoniae strains [5].
Since then, several outbreaks have been reported
in a number of European countries and the USA,
and the problem has reached endemic dimensions
in several places worldwide. The selective pres-
sure of the use and overuse of the oximino-
cephalosporins, which are widely prescribed for
the treatment of serious Gram-negative nosoco-
mial infections, has led to the isolation of a large
number of ESBL enzymes worldwide, mainly
from different genera of the Enterobacteriaceae
[6].
This review focuses on the types, molecular
characteristics of ESBLs, the methods for their
detection, their epidemiology, and antibiotic strat-
egies to prevent and control their prevalence.
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TYPES AND MOLECULAR
CHARACTERISTICS
Most ESBL enzymes contain a serine at the active
site and belong to Ambler’s molecular class A [7].
A classification scheme devised by Bush et al. [8],
in 1995, placed b-lactamases into functional
groups using their biochemical properties,
molecular structure and nucleotide sequence of
the genes. According to this scheme, ESBLs are
defined as b-lactamases that hydrolyse oximino-
cephalosporins and are inhibited by clavulanic
acid; they are placed into group 2be. ESBLs are
not active against cephamycins, and therefore
most strains expressing ESBLs should be suscept-
ible to cefoxitin and cefotetan. However, owing to
the loss of an outer membrane porin protein,
ESBL-producing strains are often resistant to
cephamycins [9,10].
Most ESBLs are TEM and SHV enzyme deriv-
atives characterised by a few point mutations at
selected loci within the gene [8,11]. As of 25
January 2005, there were 138 TEM- (TEM-1 to
TEM-139) and 62 SHV-type (SHV-1 to SHV-63)
b-lactamases, mostly found in K. pneumoniae and
E. coli strains (http://www.lahey.org/studies/
webt.htm).
They are being reported with increasing fre-
quency in various genera of Enterobacteriaceae,
such as Salmonella spp., Enterobacter aerogenes,
Proteus mirabilis, Providencia rettgeri and Morganel-
la morganii; TEM-42 has been described from
Pseudomonas aeruginosa and TEM-17 from a blood
isolate of Capnocytophaga ochracea [12–19]. The first
TEM detected enzyme, TEM-1, is still the most
commonly encountered b-lactamase in Gram-
negative bacteria. TEM-1 is responsible for amp-
icillin resistance in E. coli and ampicillin and
penicillin resistance in Haemophilus influenzae and
Neisseria gonorrhoea; it is able to hydrolyse peni-
cillins and first-generation cephalosporins [20].
TEM-2 has a single amino-acid substitution from
the original TEM-1 that does not, however,
change its substrate profile [21]. The first real
ESBL to be described in 1983 was TEM-3 and, in
subsequent years, over 100 additional TEMs have
been isolated. The combinations of amino-acid
substitutions that occur within the TEM enzymes
at a limited number of positions result in a variety
of subtle alterations, such as the ability to hydro-
lyse specific oximino-cephalosporins (ceftazidime
and cefotaxime), and changes in the isoelectric
point (which ranges from 5.2 to 6.5) [8]. A number
of amino-acid residues are particularly important
for displaying the ESBL phenotype. They include
arginine to either serine or histidine at position
164, glycine to serine at position 238 and glutam-
ate to lysine at position 240 [6].
Unlike the TEM-type b-lactamases, there are
fewer derivatives of SHV-1. The majority are
characterised by the substitution of serine for
glycine at position 238, which is critical for the
efficient hydrolysis of ceftazidime, whereas a
number of variants related to SHV-5 possess a
substitution of lysine for glutamate at position 240,
leading to efficient hydrolysis of cefotaxime [5,22].
In Greece, 13 years ago, an ESBL (SHV-5 type)
responsible for ceftazidime resistance was discov-
ered in K. pneumoniae strains [23]. Cross-resistance
of the latter strains to aminoglycosides stimulated
the search for resistance mechanisms in multire-
sistant K. pneumoniae strains. This investigation
was considered to be very important, as empirical
treatment of serious nosocomial infections in most
Greek tertiary hospitals was usually initiated with
a combination of an advanced cephalosporin plus
an aminoglycoside. A multiresistant transferable
plasmid encoding the SHV-5 b-lactamase, causing
unusually high resistance to ceftazidime and
aztreonam, and the combination of acetylating
enzymes, AAC(6¢)-I + AAC(3)-I, producing resist-
ance to all clinically available aminoglycosides,
was established in K. pneumoniae [24].
In the early 1990s, b-lactamases resistant to
clavulanic acid and sulbactam inhibition (inhibi-
tor-resistant TEM b-lactamases) were discovered,
exhibiting resistance at the clinical level to the b-
lactam–b-lactamase inhibitor combinations of
amoxicillin–clavulanate, ticarcillin–clavulanate
and ampicillin–sulbactam (but inhibition by tazo-
bactam was retained), and subsequently to pip-
eracillin–tazobactam [6,25–27]. Despite the fact
that IRTs are not real ESBLs, as are classical TEM
and SHV enzyme derivatives, they should be
discussed with ESBLs. Therefore, they have been
renamed with numerical TEM designations.
There are at least 23 distinct IRT enzymes
(http://www.lahey.org/studies/webt.htm), pri-
marily detected in France, and found mainly in
clinical isolates of E. coli, but also in some strains
of K. pneumoniae, Klebsiella oxytoca, P. mirabilis and
Enterobacter cloacae [28,29]. The sites of IRT amino-
acid substitutions are distinct from those of ESBL
point mutations, occurring at a few specific
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amino-acid residues, such as methionine at posi-
tion 69, arginine at positions 244 and 275 and
asparagine at position 276 [30–32]. However,
recently, the TEM-50 enzyme, with common
amino-acid substitutions to both ESBLs and IRTs,
has been described, conferring slight resistance to
oximino-cephalosporins [33]. Possibly, this newer
enzyme demonstrates a new group of b-lactamas-
es with a more complex phenotype.
The so-called CTX-M enzymes are a relatively
new family of plasmid-mediated ESBLs, which
preferentially hydrolyse cefotaxime and are better
inhibited by tazobactam than by sulbactam and
clavulanate (Table 1). These enzymes are not very
closely related to TEM and SHV b-lactamases as
they show only 40% identity with these enzymes
[34]. Such enzymes have been mainly detected in
Salmonella typhimurium and E. coli [6]. It seems
that the serine residue at position 237, which is
present in CTX-M enzymes, has an important role
in their extended spectrum of activity [6]. Strains
expressing the CTX-M-type b-lactamases have
been isolated worldwide, numbering 29 enzymes,
and have been associated with local outbreaks in
Japan, South America and eastern Europe; an
endemic focus has also been reported from Spain
[35–37]. Recently, in Greece, six E. coli strains with
the ESBL phenotype have been analysed [38]. All
were resistant to the combinations of amoxicillin–
clavulanate and ampicillin–sulbactam; four were
also resistant to cefoxitin, but all were susceptible
to piperacillin–tazobactam. In these strains, a new
CTX-M enzyme, differing from CTX-M-15 by one
amino-acid substitution in position 109 (aspara-
gine to serine), was isolated, conferring a lower
level of resistance to ceftazidime compared with
cefotaxime (MICs of 16 lg ⁄mL vs. > 512 lg ⁄mL).
Fifteen classical OXA-type b-lactamases also
belong to the ESBL family. However, they differ
from TEM and SHV enzymes by their classifica-
tion to molecular class D and functional group 2d
and their poor inhibition by clavulanic acid [8].
They confer resistance to ampicillin and first-
generation cephalosporins, but weak resistance to
oximino-cephalosporins, when cloned in Entero-
bacteriaceae. In order to confer the ESBL pheno-
type, either of two mutations is required: an
asparagine for serine at position 73 or an aspartate
for glycine at position 157 [6,39]. In contrast with
most ESBL enzymes, they have been mainly
isolated in P. aeruginosa and provide high-level
resistance to ceftazidime [40]. It should be pointed
out that many new members of the OXA
b-lactamases, such as OXA-20, OXA-22, OXA-24,
OXA-25, OXA-26, OXA-27 and OXA-30, do not
belong to the ESBL family [41–45].
Almost 10 years ago, PER-1, the first of a series of
novel ESBLs not closely related to any of the
well-known families of b-lactamases, was reported
[46]. It was discovered in Turkey from P. aeruginosa
strains and later from strains of S. typhimurium and
Acinetobacter baumannii [47–49]. A related enzyme,
PER-2, with 86% amino-acid homology with
PER-1, was exclusively reported from Argentina
in 1996 [50]. Subsequently, at least seven novel
unrelated ESBLs have been reported from several
parts of the world, isolated from different species of
Enterobacteriaceae (Table 2).
METHODS FOR DETECTING ESBLs
The steadily increasing prevalence of ESBL-pro-
ducing Enterobacteriaceae worldwide has created
a great need for accurate techniques of laboratory
testing for identification. It is very important to
emphasise that, according to the NCCLS inter-
pretive definitions, ESBLs do not always increase
MICs to levels characterised as resistant [51,52].
On the other hand, according to the NCCLS, an
inhibitory zone of £ 22 mm for ceftazidime,
£ 27 mm for cefotaxime and aztreonam and
£ 25 mm for ceftriaxone should raise suspicion
of ESBL production [52]. The lack of sensitivity
and specificity of traditional dilution or disc
diffusion susceptibility tests for the detection of
ESBLs has prompted the development of a variety
of fairly accurate methods based on the observa-
tion that, in clinical microbiology tests, ceftazi-
dime or cefotaxime in combination with a b-
lactamase inhibitor, usually clavulanate, which
inhibits ESBLs, reduces the level of resistance to
the former cephalosporins. The following tests
based on clinical microbiological techniques have
been applied.
1 The double-disc approximation test [53]. This
was one of the first detection methods and is
based on the Kirby–Bauer diffusion technique.
A susceptibility disc containing amoxicillin–
clavulanate is placed in the centre of a Mueller–
Hinton agar plate, and a disc containing one of
the oximino-b-lactam antibiotics (e.g., ceftazi-
dime) is placed 30 mm (centre to centre) from
the amoxicillin–clavulanate disc. The clavula-
nate diffuses through the agar and inhibits the
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b-lactamase surrounding the ceftazidime disc.
Enhancement of the zone of the ceftazidime
disc on the side facing the amoxicillin–clavul-
anate disc is interpreted as a positive test.
2 The Etest ESBL strip (AB Biodisk, Solna, Swe-
den) [6]. In this method the zone of inhibition is
read from two halves of the strip containing
ceftazidime alone or ceftazidime plus clavula-
nate. A decrease in the MIC of ceftazidime of
more than three dilutions in the presence of
clavulanate is interpreted as a positive test.
However, the Etest ESBL strip is sometimes
difficult to interpret with weak enzyme pro-
ducers that are expressed with low ceftazidime
MICs, because clavulanate may diffuse to the
side that contains ceftazidime alone.
3 Commercialised tests with discs containing
clavulanate plus ceftazidime or cefotaxime
(10 lg plus 30 lg, respectively). These methods
have been shown to detect accurately the
presence of ESBLs when an increase of
‡ 5 mm in the inhibitory zone of ceftazidime
or cefotaxime plus clavulanate compared with
controls (i.e., single cefotaxime or ceftazidime
disc) is observed [54,55].
4 The three-dimensional test. This method is
considered to be very sensitive for the detection
of ESBLs, but is technically difficult and labour
intensive, requiring experienced clinical micro-
biologists to interpret the results [56].
5 The automated ESBL microbial susceptibility
test system Vitek (BioMe´rieux, Marcy l’Etoile,
France) [6]. This method utilises either ceftaz-
idime or cefotaxime alone and in combination
with clavulanic acid (4 lg ⁄mL). A predeter-
mined reduction in growth in wells containing
clavulanate, compared with those containing
each single drug, indicates the presence of an
ESBL. Sanders et al. [57], in a study of Klebsiella
spp. and E. coli possessing well-known b-lacta-
mases, showed that the Vitek ESBL test was
99% sensitive and specific for the detection of
ESBLs. However, Tzelepi et al. [58] reported
that the Vitek ESBL detection test failed to
detect the majority of ESBL-producing strains
of Enterobacter spp. Moreover, in a European
survey, after applying the Vitek test, 37% of
ESBL-producing organisms were mistakenly
reported as being susceptible to extended-spec-
trum cephalosporins (ESCs) [59].
6 Recently, the NCCLS has recommended initial
screening by testing for growth in a broth
medium containing 1 lg ⁄mL of one of five
extended-spectrum b-lactam antibiotics [52]. A
positive result should raise suspicion of the
presence of an ESBL. This initial screening
should be followed by a phenotypic confirmat-
ory test for the determination of MICs of either
ceftazidime or cefotaxime, with and without
the presence of clavulanic acid (4 lg ⁄mL). A
decrease in the MIC of three or more twofold
dilutions in the presence of clavulanate is
indicative of the presence of an ESBL.
It should be pointed out that, if an ESBL is
detected, the strain should be reported as non-
susceptible to all ESCs and aztreonam, regardless
of the susceptibility test result [52]. However, it
should be noted that false positive ESBL results
can occur when strains produce high SHV-1
levels or when an AmpC-type enzyme is
expressed in the same isolate [60–63].
To conclude, it seems that the double-disc
approximation test and the broth dilution MIC
reduction method are the easiest and most
Table 2. Novel unrelated extended-spectrum b-lactamases (http://www.lahey.org/studies/webt.htm)
b-Lactamase Related to pI Substrate Origin Host
BES-1 Penicllinase from
Yersinia enterocolitica
7.5 CTX, CAZ, ATM Brazil Serratia marcescens
FEC-1 8.2 CTX Japan Escherichia coli
GES-1 Penicillinase from
Proteus mirabilis
5.8 CAZ French Guiana Klebsiella pneumoniae
CME-1 VEB-1 >9.0 CAZ Chryseobacterium meningosepticum
PER-1 PER-2 5.4 CAZ France Pseudomonas aeruginosa
PER-2 PER-1 5.4 CAZ Argentina Salmonella typhimurium
SFO-1 AmpA from
Serratia fonticola
7.3 CTX Japan Enterobacter cloacae
TLA-1 CME-1 9.0 CAZ, CTX, ATM Mexico Escherichia coli
VEB-1 PER-1, PER-2 5.35 CAZ, ATM Vietnam ⁄Thailand Escherichia coli
IBC-1 IBC-2, GES-1 6.9 CAZ Greece Enterobacter cloacae
IBC-2 IBC-1, GES-1 5.8 CAZ Greece Pseudomonas aeruginosa
CTX, Cefotaximase; CAZ, Ceftazidime; ATM, Aztreonam.
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cost-effective for application by clinical laborat-
ories.
In order to identify the specific ESBL expressed
in a clinical isolate, more laborious and compli-
cated methods are required. The determination of
the isoelectric point was used in the past, but is no
longer adequate to characterise the exact ESBL, as
different b-lactamases possess identical isoelectric
points. The following molecular detection meth-
ods have been applied [6]: (i) specific DNA
probes; (ii) polymerase chain reaction (PCR) with
oligonucleotide primers; (iii) oligotyping; (iv)
PCR followed by restriction fragment length
polymorphism analysis; (v) PCR–single-strand
conformational polymorphism analysis; (vi) ligase
chain reaction; (vii) nucleotide sequencing. All of
these methods share several advantages and
drawbacks, except the latter, which represents
the standard, detecting all specific b-lactamase
genes present in a strain [64]. However, it is
labour intensive and technically challenging,
whereas manual methodology is difficult to
interpret.
According to the NCCLS guidelines, and as
already mentioned, many ESBL-producing iso-
lates are not always phenotypically resistant to
oximino-cephalosporins. However, patients suf-
fering from infections caused by ESBL-producing
organisms are at risk of treatment failure if an
ESC is prescribed [65,66]. Therefore, it is imper-
ative for the clinical microbiology laboratory to
identify isolates that possess increased MICs
(‡ 2 lg ⁄mL) to oximino-cephalosporins, even
though they may be equal to or below the
susceptibility breakpoint (MIC £ 8 lg ⁄mL), and
subsequently to implement one of the reported
methods to detect ESBLs [51,67,68]. On the other
hand, in order to avoid misleading results for the
clinician, and according to NCCLS recommenda-
tions, it is very important that any Klebsiella sp. or
E. coli that is confirmed as an ESBL producer
should be reported as being resistant to all
cephalosporins, penicillins and aztreonam,
regardless of the susceptibility test result [52].
The inoculum effect demonstrated by many
ESBL-producing strains should also be of great
concern. Medeiros and Crellin [69] found that the
MIC rose dramatically when the inoculum in the
susceptibility tests was increased from 105 to
107 cfu ⁄mL, an effect also demonstrated in animal
models of intra-abdominal abscesses and infec-
tious endocarditis. In addition, in many human
infections, such as meningitis, endocarditis, septic
arthritis, osteomyelitis and various abscesses,
the bacterial load may even exceed such high
inoculum levels, reaching colony counts of
109)1010 cfu ⁄mL or gram of tissue [70,71].
Recently, Thomson and Smith-Moland [72] stud-
ied in vitro the influence of the inoculum effect on
meropenem, cefotetan, cefotaxime, ceftazidime,
ceftriaxone, cefepime, aztreonam and piperacillin
against strains of Klebsiella, Escherichia, Enterobact-
er, Citrobacter, Serratia, Morganella and Proteus spp.
that produced 22 different ESBLs. An inoculum
effect, defined as an eight-fold or greater MIC
increase on testing with the higher inoculum
(105 cfu ⁄mL vs. 107 cfu ⁄mL), was most consis-
tently detected with cefepime, cefotaxime and
ceftriaxone, and less frequently with meropenem
and cefotetan, whereas piperacillin–tazobactam
was intermediate between these two groups of
agents. Despite previous suggestions, the latter
in-vitro results confirm that, until prospective
reliable clinical results exist, cefepime should not
be considered as the therapy of choice in serious
infections in which ESBL strains are implicated.
With regard to piperacillin–tazobactam, inoculum
effects occurred in tests with strains producing
SHV-derived ESBLs, and only occasionally in
tests with strains producing TEM-derived ESBLs
[72]. The relevance of these in-vitro findings must
be tested with reliable clinical data.
EPIDEMIOLOGY
The ESBL phenomenon was first reported in
Germany almost 20 years ago, but it did not take
long to become established elsewhere, including
in the USA and Asia [5,6]. In the USA, K. pneumo-
niae resistance rates to ceftazidime increased from
4% in 1990 to 14% in 1993 [73]. However, in a
study by Fridkin et al. [74], involving intensive
care unit (ICU) patients in the USA in 1996–97,
only 3.7% of K. pneumoniae were reported to be
resistant to third-generation cephalosporins,
whereas in the NNIS ⁄ ICARE and SENTRY stud-
ies (1999 and 1997–99), respectively, the corres-
ponding values were 9% and 10%, respectively
[74,75]. A surveillance of antibiotic resistance in
European ICUs for the years 1990–1999 revealed a
wide variation in ESBL producers, with the
highest prevalence of 73% observed in Turkey.
ICUs in Portugal, France and Russia also showed
a significant problem with resistance rates of 34%,
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36% and 33%, respectively [76]. In contrast,
Belgian, German, Spanish and Swedish ICUs
had only a 1–4% prevalence of suspected ESBL-
producing Klebsiella spp. for the years 1994–95. In
a study organised by Livermore and Yuan [59] in
1994, a high prevalence of ESBL in Klebsiella spp.
was observed in Belgium (31%), France (24%),
Italy (17%), the Netherlands (16%), Portugal
(49%) and Turkey (59%), with no ESBL detected
in the UK, and low rates in Spain (1%), Greece
(5%) and Germany (9%). However, the data from
the most recent European SENTRY study, per-
formed mainly in southern Europe, showed a
39% mean prevalence of suspected ESBL-produ-
cing Klebsiella spp., with the worst situation
reported, once more, from Turkey [76]. The large
variation amongst the participating countries in
Europe is probably indicative of ESBL outbreaks.
With regard to ESBL-producing E. coli strains,
Turkey is the country with the highest resistance
rate (26%), while, in the European SENTRY
study, 9% of E. coli strains, mostly collected from
southern European countries, were resistant to
ceftazidime [76]. In the study by Hanberger et al.
[76], 0–4% of E. coli isolates reported in European
studies were resistant to ceftazidime, a rate
similar to the 3% prevalence of ceftazidime
resistance reported from ICUs in the USA. In
Japan, in a recent survey of 196 institutions across
the country, only < 0.1% of E. coli and 0.3% of
K. pneumoniae strains expressed an ESBL, whereas
corresponding figures for ESBL production in
E. coli and K. pneumoniae from Korea, Taiwan and
Hong Kong were 4.8%, 8.5% and 12%, respect-
ively [77–80].
Surveys in both the USA and Europe have
indicated that SHV-4 and SHV-5 are the most
common ESBLs, while the predominant TEM
types in the USA (TEM-10, TEM-12, TEM-26) are
different from those in Europe (TEM-3, TEM-24)
[81,82]. However, recently, TEM-10 was reported
with the same frequency from Portugal and the
UK [6,83,84]. Outbreaks of TEM-47 in Poland and
TEM-52 in Korea have also been reported
recently, while SHV-5 b-lactamase is encountered
worldwide, with reports from France, Croatia,
Greece, Hungary, Poland, the UK, the USA and
South Africa [6]. It therefore seems that ESBLs
arise and disseminate locally, but the spread of
particular ESBL types or ESBL-producing strains
can also occur between hospitals that exchange
patients. Recently, in several Greek ICUs, a
multiresistant K. pneumoniae strain with border-
line susceptibility to gentamicin (MIC ¼
4 lg ⁄mL) and sensitive only to colimycin caused
local outbreaks; it has already become endemic in
some ICUs. Such strains harbour, on the same
plasmid, not only SHV-5, but also a VIM-1 like
enzyme conferring additional resistance to carb-
apenems (H. Giamarellou, unpublished observa-
tions, 2004).
With regard to non-E. coli, non-Klebsiella
Enterobacteriaceae species producing ESBLs,
E. aerogenes seems to predominate. Nosocomial
outbreaks in ICUs caused by cross-colonisation
have been reported in France, Belgium and
Austria, where the dissemination of epidemic
clones of multiresistant E. aerogenes harbouring
ESBLs, and particularly TEM-24, has been
observed [6,76,85].
Recently, outbreaks of organisms producing
multiple b-lactamases have been described. This
combination comprises non-ESBL class A
enzymes and chromosomal AmpC-type enzymes
together with ESBLs. Similar strains express
resistance to b-lactam–b-lactamase inhibitor com-
binations, cephamycins, oximino-cephalosporins,
aztreonam and even carbapenems [6]. Surpris-
ingly, a high association with resistance to quino-
lones has been observed in strains producing
ESBL enzymes. Paterson et al. [86] reported that,
among ciprofloxacin-resistant strains, 60% were
ESBL producers, compared with 16% in ciprofl-
oxacin-susceptible strains (p ¼ 0.0001).
The epidemiological characteristics of ESBL
outbreaks have been studied by several investi-
gators. The risk factors associated with the acqui-
sition of ESBL-producing organisms are described
in Table 3 [87–93]. Lautenbach et al. [94] studied
Table 3. Risk factors associated with extended-spectrum
b-lactamase-producing organisms in case–control studies
[87–93]
Nosocomial infection
Previous administration of any antibiotic
Previous administration of ceftazidime or aztreonam
High Acute Physiology and Chronic Health Evaluation
(APACHE) II score
Ventilatory assistance
Urinary catheter
Arterial catheter
Central venous catheter
Gut colonisation
Emergency abdominal surgery
Gastrostomy or jejunostomy tube
Length of hospital stay
Length of intensive care unit stay
Age
Nursing home residence
Low birth weight
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the risk factors for infection and the impact of
resistance on outcomes when ESBL-producing
E. coli and K. pneumoniae were implicated. Thirty-
three patients with infection due to ESBL-produ-
cing E. coli or K. pneumoniae (case patients) were
compared with 66 matched controls. Total previ-
ous antibiotic use was the only independent risk
factor for ESBL-producing E. coli or K. pneumoniae
infection (odds ratio, 1.10; 95% confidence inter-
val, 1.03–1.18; p ¼ 0.006). Case patients were
treated with an effective antibiotic a median of
72 h after infection was suspected, compared with
a median of 11.5 h for controls (p < 0.001).
Infections caused by ESBL-producing E. coli or
K. pneumoniae were associated with a significantly
longer duration of hospital stay and greater
hospital charges (p ¼ 0.01 and p < 0.001, respec-
tively). The authors emphasised that ESBL-pro-
ducing E. coli and K. pneumoniae infections have a
significant impact on several important clinical
outcomes, and efforts to control outbreaks of
infection with similar strains should emphasise
the judicious use of all antibiotics as well as
barrier precautions to reduce their spread.
INTERVENTIONS FOR THE
THERAPY, CONTROL AND
PREVENTION OF INFECTIONS
CAUSED BY ESBL-PRODUCING
GRAM-NEGATIVE
MICROORGANISMS
ESBL-producing Enterobacteriaceae are, as a rule,
resistant to all cephalosporins and extended-
spectrum penicillins, including the monobactam
aztreonam, while resistance to trimethoprim–sul-
famethoxazole and aminoglycosides is frequently
co-transferred on the same plasmid [95]. There-
fore, therapeutic choices are limited. However,
several reports in the literature describe the
results obtained after the prescription of cefotax-
ime or ceftazidime for ESBL-producing microor-
ganisms. One of the larger studies was reported
by Meyer et al. [96], who documented a 2-year
outbreak of ESBL-producing K. pneumoniae with
155 colonised or infected patients. Therapy
and outcome were evaluated in 43 infected
patients. Thirteen of 13 patients with invasive
infection, who did not receive therapy directed
against ESBLs, died, whereas two patients
with non-bacteraemic bacteriuria responded to
cephalosporins. Naumovski et al. [97] reported
their experience with ESBL-producing K. pneumo-
niae bacteraemia in four cancer patients. Two
patients who received ceftazidime alone died, but
two patients in whom tobramycin was added to
ceftazidime survived. In a global study of more
than 200 cases of K. pneumoniae bacteraemia from
seven hospitals on five continents, 15% of cases
with ESBL isolates were compared with 85% of
cases with non-ESBL isolates [91]. In 84% of
ESBL cases, bacteraemia was hospital acquired,
compared with only 43% of non-ESBL cases.
In 31% of ESBL cases, a third-generation cepha-
losporin had recently been prescribed, compared
with only 3% of non-ESBL cases. However,
piperacillin–tazobacam and imipenem use were
not associated with ESBL infections. The crude
mortality rate of patients with ESBL bacteraemia
was 46%, compared with 34% in the non-ESBL
group. Finally, it is noteworthy that, amongst
patients with ESBL-producing K. pneumoniae
bacteraemia, who received initial empirical ther-
apy to which the organism was resistant, 75%
died, compared with 28% who received initial
empirical therapy to which the organism was
susceptible.
In an attempt to clarify whether screening of
Klebsiella spp. or E. coli for ESBL was clinically
necessary, Paterson et al. [98] performed a pros-
pective, multinational study of K. pneumoniae
bacteraemia, and identified 10 patients with
ESBL-producing strains who were treated with
cephalosporins and whose infecting organisms
were not resistant in vitro to the utilised cepha-
losporin. In the same study, 26 similar cases of
severe infections which had previously been
reported were also reviewed. In a total of 32
evaluated cases, 100% (4 ⁄ 4) patients experienced
clinical failure when the MICs of the cephalosp-
orin used for treatment were in the intermediate
range, and 54% (15 ⁄ 28) experienced failure when
the MICs of the cephalosporin used for treatment
were in the susceptible range. The authors con-
cluded that it is clinically important to detect
ESBL production by Klebsiella spp. or E. coli, even
when cephalosporin MICs are in the susceptible
range (£ 8 lg ⁄mL), and to report ESBL-producing
organisms as resistant to aztreonam and all
cephalosporins.
Wong-Beringer et al. [99] recently investigated
the molecular correlation of treatment outcomes
in bloodstream infections caused by E. coli and
K. pneumoniae with reduced susceptibility to
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ceftazidime. They described the largest treatment
experience of a non-outbreak series of blood-
stream infections caused by strains of E. coli (23
episodes) and K. pneumoniae (13 episodes) with
ceftazidime MICs of ‡ 2 lg ⁄mL. E. coli isolates
produced a greater variety of b-lactamase types
than did K. pneumoniae isolates, among which
ESBL production was predominant. Five ESBL
types were identified: TEM-12, TEM-71, TEM-6,
SHV-12 and SHV-5. Most patients were treated
empirically with an ESC-based regimen. A
favourable response to treatment with a non-
ceftazidime ESC was observed when the causat-
ive pathogen produced either TEM-6 or TEM-12,
whereas ceftazidime treatment was associated
with failure of therapy in all patients. Despite
the limited clinical success, ESCs were not recom-
mended for the treatment of serious infections
caused by ESBL-producing strains. With regard,
in particular, to the choice of cefepime as empir-
ical therapy for Gram-negative bacillary infec-
tions in centres in which ESBL-producing bacteria
predominate, the fact that the incidence of
Enterobacteriaceae also carrying plasmid-
mediated AmpC-type b-lactamases is increasing
mandates the need for prospective studies to
explore its specific role in such situations [100].
Until then, and despite favourable in-vitro sus-
ceptibility results, cefepime should not be recom-
mended.
Initially, it was believed that TEM and SHV
ESBLs did not hydrolyse the cephamycins; there-
fore, cefoxitin and cefotetan could be adminis-
tered for the therapy of proven or suspected
infections with ESBL producers. However, it
seems that, quite often, such strains also possess
a plasmid-mediated AmpC-type b-lactamase that
effectively hydrolyses cephamycins. In addition,
porin-deficient mutants of K. pneumoniae have
been described which are selected in vitro during
therapy with cefoxitin or cefotetan [10,68].
With regard to the critical question of
‘whether b-lactamase inhibitors are of therapeu-
tic value in the case of infections caused by
ESBL-producing K. pneumoniae’, there has been
much consideration. Piroth et al. [101] conducted
a case–control study in an ICU in order to
investigate the risk of acquisition of ESBL strains,
with special reference to therapy with b-lacta-
mase inhibitors and resuscitation procedures.
Fifty-one patients colonised or infected with
ESBL-producing K. pneumoniae (cases) were
matched with 51 non-colonised patients (con-
trols). The duration of intubation was signifi-
cantly longer for cases than for controls, while
the duration of b-lactamase inhibitor therapy
was significantly shorter. By means of multiva-
riate analysis, intubation was the only risk factor
identified, while b-lactamase inhibitor therapy,
80% of which included clavulanic acid and 20%
tazobactam, was shown to be a protective factor.
The authors concluded that, in ICUs, the prefer-
ential use of b-lactamase inhibitors may help
control the emergence and spread of these
pathogens if essential hand-washing and isola-
tion procedures are adhered to. It has also been
reported that the administration of b-lactamase
inhibitors may facilitate, at least in vitro, their
reverse mutation into less harmful enzymes.
However, clinical isolates of ESBL-producing
K. pneumoniae, because of the hyperproduction
of ESBL, have been proven to be less susceptible
to b-lactam–b-lactamase inhibitor combinations,
and the selection of Gram-negative bacteria
producing AmpC-type b-lactamases is always a
risk [102].
When ESBL isolates are susceptible in vitro,
therapy with a fluoroquinolone should be satis-
factory in vivo [95]. However, as already men-
tioned, fluoroquinolone resistance often coexists
in ESBL-producing organisms, probably due to
pre-existing risk factors, such as exposure to
antimicrobial agents that are given to hospitalised
patients who acquire such strains [102,103]. A
recent report is of special concern for clinicians, as
it has documented a transferable fluoroquinolone
resistance in K. pneumoniae on a plasmid that also
encodes an AmpC-type b-lactamase.
The literature refers to several scattered cases of
patients successfully treated with a carbapenem,
who were mostly suffering from bacteraemia or
meningitis caused by ESBL-producing microor-
ganisms [100]. On the other hand, for similar
strains, in-vitro susceptibility results reported
imipenem MICs of £ 1.0 lg ⁄mL [100]. It is still
uncertain whether combination therapy is neces-
sary and which antibiotic, when combined with a
carbapenem, will achieve an optimal outcome
in vivo. In-vitro combinations of imipenem with
amikacin or ciprofloxacin against blood isolates of
ESBL-producing K. pneumoniae did not result in
synergistic interactions [100]. Because of insuffi-
cient clinical information, many investigators
prefer imipenem and meropenem as the drugs
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of choice for serious infections due to ESBL-
producing strains. However, Wong-Beringer et al.
[99] suggested that, in the case of a non-outbreak
situation, clinicians, in order to preserve the
therapeutic value of carbapenems, need not
administer a carbapenem. Based on institutional
patterns of susceptibility results, piperacillin–ta-
zobactam, a fluoroquinolone or an aminoglyco-
side would be preferable. In contrast, in the case
of life-threatening infections or in an outbreak
setting, empirical therapy would call for a carb-
apenem. However, it is noteworthy that, in
centres with ESBL outbreaks, the frequency of
isolating carbapenem-resistant P. aeruginosa and
Acinetobacter spp. increased dramatically as a
result of the increased use of this class of
antibiotic [103]. For similar strains, only colimycin
remains active in vitro with moderate in-vivo
results [104,105]. Clinicians should also be aware
that, during therapy with a carbapenem, bacteria
intrinsically resistant to imipenem, such as
Stenotrophomonas maltophilia and vancomycin-
resistant Enterococcus faecium, can be selected.
It is evident that no prospective studies exist to
elucidate the various treatment options and out-
comes for serious infections caused by ESBL-
producing organisms. Therefore, appropriately
organised prospective trials in centres with en-
demic ESBL-producing bacteria are urgently
required.
The epidemiological characteristics of ESBL
outbreaks indicate that the problem may be
attributed to clonal dissemination, antibiotic
selective pressure on plasmid dissemination
amongst distinct clones, or both. One of the
earliest ESBL outbreaks was reported in Massa-
chusetts by Rice et al. [95], concerning a chronic
case facility. ESBLs were detected in five different
species, i.e., K. pneumoniae, E. coli, Enterobacter
agglomerrans, Citrobacter divs. and Serratia spp.,
indicating resistant plasmid dissemination. In
another study involving 43 USA medical centres
in 26 states, extensive strain diversity was docu-
mented, whereas, in France, five nosocomial
outbreaks in three hospital wards involved four
distinct strains, TEM-3 ESBL being responsible for
plasmid dissemination and SHV-4 for clonal
dissemination [106]. Therefore, both isolation
procedures (e.g., gloves, gowns) and application
of hand hygiene, according to the recent CDC
guidelines, as well as appropriate antibiotic utili-
sation policies, should be considered [107].
Reasons to control ESBL producers in particular
include: (i) the potential transfer of multiple
antibiotic resistance as a result of genes found
on large plasmids that may also carry resistance
determinants to other classes of antibiotics, such
as aminoglycosides and sulphonamides; (ii) their
association with nosocomial outbreaks character-
ised by high morbidity and mortality rates; (iii)
the need to limit the excessive use of broad-
spectrum antibiotics; and (iv) the need to limit
outbreaks by controlling resistance. In addition,
as we face the so-called ‘End of Antibiotics’ era,
the application of various methods to control
antimicrobial use, in an effort to reverse resist-
ance, is of extreme importance [108]. Selective
removal, control or restriction and, recently,
cycling of antibiotics, have been suggested [109].
The value of restriction policies to reverse resist-
ance caused by ESBLs has been proven in several
studies. Rice et al. [110], in 1996, described the
control of a ceftazidime-resistant K. pneumoniae
outbreak at the Cleveland VA Medical Center
which reached almost 30% in 1994. Interventions
included: (i) encouragement of avoidance of ceft-
azidime; (ii) education of hospital staff concerning
the outbreak; and (iii) selection of piperacillin–
tazobactam as an alternative to ceftazidime. The
latter choice was based on the antimicrobial activ-
ity of piperacillin–tazobactam, which is at least as
broad as the ceftazidime antimicrobial spectrum,
and, in contrast with a cephalosporin agent, covers
also enterococci and resistant Enterobacter spp.,
simultaneously avoiding imipenem. After repla-
cing 50% of ceftazidime use with use of piperacil-
lin–tazobactam, resistance rates decreased from
28% to 10%. In this study, no emphasis or increase
in compliance with infection control measures was
observed, suggesting that antibiotic restriction was
the most important intervention in the clonal
outbreak. In an effort to determine whether restric-
tion of the cephalosporin class would reduce the
incidence of infection or colonisation by cepha-
losporin-resistant Klebsiella spp., and to determine
whether the restriction of cephalosporins would
further increase imipenem use and resistance in P.
aeruginosa, Rahal et al. [111] conducted a before and
after comparative 2-year trial at a New York hospi-
tal. A new antibiotic guideline excluded the use of
cephalosporins, except for paediatric infection,
single-dose surgical prophylaxis, acute bacterial
meningitis, spontaneous bacterial peritonitis and
outpatient gonococcal infection. All other cepha-
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losporin use required prior approval by the infec-
tious disease section. During the study, a signifi-
cant decrease in overall cephalosporin use was
noted (80.1%), with a 72.5% decrease in ceftazi-
dime consumption; this was followed by a signi-
ficant decrease in ceftazidime-resistant Klebsiella
isolates (44%), including both infecting strains and
colonisers [combined ICUs, 70.9% (p < 0.001);
surgical ICU, 87.5% (p < 0.001)]. However, imipe-
nem use was increased by 140.6%, followed by a
subsequent increase of 68.7% in imipenem-resist-
ant P. aeruginosa (p < 0.01).
Pena et al. [92] reported their results after an
outbreak of ESBL-producing K. pneumoniae in
Barcelona, during which 145 patients were
colonised or infected (72% in ICU) and 63%
developed infection, with primary bacteraemia in
43%. Interventions during more than a 2-year
period included: (i) the use of aprons and cohort-
ing, with heightened awareness of hand-washing
and glove use; (ii) education initiatives; (iii)
restriction of the use of oximino-cephalosporins;
and (iv) the empirical use of imipenem or pip-
eracillin–tazobactam for nosocomial ICU infec-
tions. After reduction of oximino-cephalosporins
by 87%, ESBL-carrying strains, predominating in
40% of isolates, almost disappeared.
Patterson et al. [112], in Texas, studied the
association of antibiotic utilisation measures and
the control of multidrug-resistant (MDR) K. pneu-
moniae after emergence in two hospitals in their
medical centre. Clonal strain dissemination was
the major mechanism of emergence at hospital A;
emergence was polyclonal at hospital B. Antibi-
otic utilisation interventions at both institutions
included physician education regarding the
association of ceftazidime use and MDR K. pneu-
moniae. At hospital A, ceftazidime use decreased
from 4.301 g in the pre-intervention period to
1.248 g in the post-intervention period, with an
increase in piperacillin–tazobactam from 12.455 g
to 17.464 g. Ceftazidime resistance in K. pneumo-
niae decreased from 22% to 15% (p < 0.05),
whereas piperacillin–tazobactam resistance
decreased from 36% to 19% (p < 0.05). At hospi-
tal B, ceftazidime use decreased from 6.533 g in
the pre-intervention period to 4.792 g in the post-
intervention period, with a piperacillin–tazobac-
tam increase from 58.691 g to 67.027 g. Resistance
in K. pneumoniae decreased from 10% to 5%
(p < 0.05) and from 22% to 14% (p < 0.05) for
ceftazidime and piperacillin–tazobactam, respect-
ively. Follow-up data showed a continued
decrease in piperacillin–tazabactam resistance
despite increased use at both hospitals. The
authors concluded that antibiotic restriction
measures may be particularly important for the
control of MDR K. pneumoniae, whether emer-
gence is clonal or polyclonal, basing their explan-
ation for the decrease in piperacillin–tazobactam
resistance, despite the increase in consumption,
on the decrease in the selection and cross-trans-
mission of ESBL-producing K. pneumoniae isolates
at hospital B and the decrease in selection and
cross-transmission of AmpC-type b-lactamase-
producing isolates at hospital A.
Recently, in a general ICU in Italy, Luzzaro
et al. [113] described a nosocomial outbreak of
MDR P. aeruginosa producing the novel PER-1
ESBL. Although the outbreak was controlled after
the application of strict hygiene measures, ulcer
disinfection with mercurochrome or silver nitrate
and broad application of carbapenems, carbape-
nem-resistant strains of Stenotrophomonas malto-
philia and Pseudomonas putida producing VIM-1
emerged in the unit.
In Greece, after the application of a ‘restricted
antibiotic programme’ in a tertiary hospital in
Athens that included all advanced antibiotics,
i.e., third- and fourth-generation cephalosporins,
carbapenems, monobactams, fluoroquinolones
and glycopeptides, total consumption decreased
by 44% (16.2 vs. 10.7 daily defined doses), with
a subsequent decrease in ceftazidime- and
piperacillin–tazobactam-resistant K. pneumoniae
strains producing ESBLs from 31% to 15%
(p < 0.001) and from 34% to 20% (p < 0.001),
respectively [114]. Cycling of antimicrobial
agents in the reported studies was not adequate
to determine whether any meaningful impact on
resistance occurs as a result of a cycling pro-
gramme [109]. However, Raymond et al. [115]
concluded that the implementation of a quar-
terly empirical antibiotic rotation schedule in an
ICU was feasible, and was associated with
significant reductions in the incidence of infec-
tion, antibiotic-resistant organism infection and
infectious mortality without an increase in anti-
biotic cost.
CONCLUSION
There is no doubt that ESBL-producing Entero-
bacteriaceae, because of their multiresistant
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pattern, create a therapeutic dilemma for the
clinician. Based on cumulative clinical experience,
carbapenems and piperacillin–tazobactam seem
to be the antibiotics of choice for the treatment of
serious infections. However, carefully controlled
prospective studies to determine the preferable
antibiotic are lacking. For the time being, infection
control measures and, particularly, compliance
with hand hygiene guidelines, as well as appro-
priate antibiotic policies, including the control of
the widespread use of advanced cephalosporins,
are urgently required to prevent and to ameliorate
the ever-increasing problem of the emergence of
MDR ESBL-producing Gram-negative microor-
ganisms.
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